Skip to content

Local Injection of PRP During Repair of Disrupted Surgical Wounds

Local Injection of Autologous Platelet Rich Plasma During Repair of Disrupted Surgical Wounds at Obstetrics and Gynecology Department: A Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03781882
Enrollment
220
Registered
2018-12-20
Start date
2019-01-01
Completion date
2020-03-31
Last updated
2020-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Role of Platelet Rich Plasma in Wound Healing

Keywords

Platelet rich plasma, disrupted wounds, Obstetrics and Gynecology

Brief summary

Patients with disrupted wounds will either managed as usual or managed by Platelet rich plasma local infiltration in the wound edges

Detailed description

The patients with disrupted surgical wounds will be cleansed, debrided and closed with infiltration of platelet rich plasma in one group and the other group will be closed without infiltration of Platelet rich plasma

Interventions

PROCEDUREPlatelet rich plasma infiltration in the wound edges

platelet rich plasma will be injected in the wound edges

PROCEDUREClosure of wound without platelet rich plasma infiltration

No infiltration of platelet rich plasma is done

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Patients were not allowed to know allocations

Intervention model description

All cases with disrupted surgical wounds admitted at Obstetrics and Gynecology departments

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Disrupted surgical wounds after cesarean sections and other gynecological operations * Body mass index 18-25 * Hemoglobin \> 10.5gm/dl * Albumin \>3.5gm/dl

Exclusion criteria

* Medical disorders asDiabetes mellitus (DM), Liver disease or systemic lupus erythymatosus (SLE) * Patient on corticosteriod therapy * Thrombocytopenia * Coagulation disorders

Design outcomes

Primary

MeasureTime frameDescription
Complete wound healing30 daystime needed for complete wound closure
Duration of hospital stay30 daysTime during which patient is admitted

Secondary

MeasureTime frameDescription
Failure of complete wound healing30 daysNo complete closure
Need fo tertiary suture30 daysneed to re-operate the case again

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026